ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

Inclusion Criteria: * 1\. Male or non-pregnant, non-breastfeeding female between 18 and 50 years of age (inclusive) at the time of consent. * 2\. Tetravalent dengue antibody response at 28 days following final vaccination for vaccinated groups of volunteers. * 3\. Volunteers must be able and willing to provide written informed consent. * 4\. Volunteers must be healthy as established by medical history and clinical examination at study entry. * 5\. Volunteers must pass a comprehension test and be able to comply with all study requirements. * 6\. Female volunteers of non-childbearing potential (non-childbearing potential is defined as having had one of the following: a tubal ligation at least 3 months prior to enrollment, a hysterectomy, an oophorectomy, or is post-menopausal). * 7\. Female volunteers of childbearing potential may be enrolled in the study, if all of the following apply: * Practiced adequate contraception (see Definition of Terms, section 5.4.2.3.) for 30 days prior to challenge * Has a negative urine pregnancy test on the day of DHIM * Agrees to continue adequate contraception until two months after completion of the DHIM * 8\. Provide consent for release of medical history records from primary care physician, college or university medical center, urgent care, or emergency room visit Exclusion Criteria: * 1\. Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits * 2\. Recent (in the past 4 weeks) travel to any dengue endemic area. These potential volunteers may be eligible for enrollment a minimum of 4 weeks later * 3\. Volunteer seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV) * 4\. Unvaccinated volunteers positive for antibodies to flaviviruses (FV) to include dengue virus, West Nile virus, Yellow Fever virus, Zika virus, and Japanese encephalitis virus. * 5\. Any history of FV infection or FV vaccination except for participation in the ADVP003 or ADVP004 dengue vaccination studies; during the study period (Note: Late time point serology from the trials can be tested concomitant to screening serology to clarify if incident FV infection has occurred between vaccination and challenge) * 6\. Medical history of, or current, diabetes, chronic obstructive pulmonary disease, peptic ulcer disease, coronary artery disease, cardiac arrhythmia, cardiomyopathy, pericarditis, or auto-immune disease * 7\. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * 8\. History of Guillain-Barré syndrome (GBS) * 9\. History of bipolar disorder, schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the volunteer from participating in the study * 10\. Safety laboratory test results at screening that are deemed clinically significant or more than Grade 1 deviation from normal with the exception of PT/PTT, fibrinogen decrease, ALT/AST increase (\<1.1 x ULN acceptable), platelet decrease which will be exclusionary at Grade 1 or higher * 11\. Significant screening physical examination abnormalities at the discretion of the investigator, including a BMI \> 35 kg/m2 * 12\. Women who intend to become pregnant or men who intend to father a child during the study period (approximately 6 months) * 13\. Female: pregnant, lactating or history of heavy menstrual bleeding menstrual periods lasting consistently and regularly longer than 6 days, or consistently and regularly requiring 5 or more pads or tampons per day, and volunteer to the opinion and review of the investigator. * 14\. Female volunteers using an intrauterine device (IUD) or Mirena® * 15\. Female volunteers with a history of clinically significant fibroids or uterine polyps, endometriosis, dysmenorrhea, adenomyosis, and uterine scarring (e.g. after D\&C), unless treated, with no active clinically significant disease * 16\. Allergy (hives, shortness of breath, swelling of the lips or throat), or hospitalization related to a previous vaccination, anaphylaxis of unknown etiology, or allergy to specific medications/animals for which antigens may be in the virus preparations to include: Shellfish allergy, Fetal Bovine Serum, L-Glutamine, Neomycin and Streptomycin * 17\. Recent blood donation within prior 56 days of inoculation or planning to donate blood in the one 1 year following inoculation with dengue virus * 18\. Receipt of blood products or antibodies within 90 days of inoculation or during the study period * 19\. Any personal beliefs that bar the administration of blood products, transfusions, or serum albumin * 20\. Participation in the 4 weeks preceding inoculation, or planned participation during the present trial period, in another clinical trial investigating a vaccine except for participation in the ADVP003 or ADVP004 study, drug, medical device, or medical procedure * 21\. Planned administration of a licensed or study vaccine not planned in the study protocol during the period starting 30 days prior to the DHIM for a live vaccine or 14 days prior to DHIM for inactivated vaccines and extending until 56 days after study completion * 22\. Planned or current administration of an HMG-CoA reductase inhibitor (i.e., lovastatin, simvastatin, atorvastatin, etc.) * 23\. Currently taking methadone or suboxone * 24\. Currently regularly taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) * 25\. Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use * 26\. Chronic or recent acute medical condition that, in the opinion of the investigator, impacts volunteer safety.